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Abstract
Different subgenogroups of enterovirus 71 (EV-71) have caused numerous outbreaks of hand, foot, and mouth
disease worldwide, especially in the Asia-Pacific region. During the development of a vaccine against EV-71, the
genetic and antigenic diversities of EV-71 isolates from Taiwan were analyzed by phylogenetic analyses and
neutralization tests. The results showed that the dominant genogroups had changed twice, from B to C and from C to
B, between 2009 and 2012. The subgenogroup B5 (B5b cluster) was dominant in 2008-2009 but was replaced by
subgenogroup C4 in 2010-2011. From the end of 2011 to 2012, the re-emerging subgenogroup B5 (B5c cluster) was
identified as the dominant subgenogroup of EV-71 outbreaks, and subgenogroups C2 and C4 were detected in
sporadic cases. Interestingly, the amino acid substitution at position 145 in the VP1 gene was observed in some
strains isolated from patients with acute flaccid paralysis. Furthermore, thirty-five strains and their corresponding
serum samples were used to analyze the cross-protections and antigenic diversities among different subgenogroups
(C4a, C5, B4, B5b, B5c, and C2-like) of EV-71. Evident antigenic diversity existed only for the C2-like subgenogroup,
which was not effectively neutralized by other serum samples. In contrast, the anti-C2-like serum sample showed
broad cross-reactivity against all other subgenogroups. Therefore, these results may provide valuable information for
the selection of EV-71 vaccine candidates and the evolution of EV-71 subgenogroups in Taiwan from 2009 to 2012.
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Introduction
As a member of the genus Enterovirus of the family
Picornaviridae, human enterovirus 71 (EV-71) is one of the
most prevalent pathogens infecting young children and may
cause outbreaks of hand-foot-mouth disease (HFMD),
herpangina, and severe neurological complications [1]. More
than one hundred serotypes have been identified in the genus
Enterovirus [2], and classified into twelve species. EV-71 and
other 23 serotypes are now members of the species
Enterovirus A (http://www.picornaviridae.com/enterovirus/
enterovirus.htm).
The EV-71 genome possesses approximately 7,500
nucleotides and encodes four structural capsid proteins (VP4,
VP2, VP3, and VP1), and seven nonstructural proteins (2A, 2B,
2C, 3A, 3B, 3C, and 3D). Untranslated regions are located at
both ends of the EV-71 genome. The capsid proteins contain
antigenic sites that correspond to virus serotyping and receptor
binding [1,3,4]. In previous studies, the VP1 protein was
identified to induce human EV-71-specific CD4+ T-cell
proliferation and was capable of eliciting neutralizing antibodies
against EV-71 [5,6]. In addition, a VP1 mutation was shown to
be the determinant of mouse adaptation and virulence [7,8].
Generally, sequencing of VP1 has been used for genotyping
and phylogenetic analysis, and three genogroups (A, B, and C)
were classified in EV-71, although the use of a combination of
VP1 and 3D RNA polymerase gene sequences was also
proposed for initial genotyping of EV-71 isolates [9].
Genogroup A contains only one strain, the prototype strain
BrCr, while genogroups B and C are each divided into five
subgenogroups (B1-B5 and C1-C5, respectively) [10,11].
Furthermore, some rare genogroups were identified
sporadically, including subgenogroups B0, C0, D, and C2-like
[9,12-15]. Although molecular biological methods have
generally been used for the rapid detection and
characterization of EV, virus isolation is still considered the
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gold standard in EV identification, and neutralization tests are
used for serotyping and antigenic grouping.
EV-71 was first isolated in California in 1969, and it has been
responsible for several outbreaks in different countries, most
recently in Cambodia [16]. Since the discovery of genogroup A
in the USA, that prototype strain was recently reported in China
in 2008 [17]. Subgenogroups B1 and B2 circulated in the USA,
Japan, Australia, and other countries between 1970 and 1990
[12,18]. Subgenogroups B3 to B5 have been described in
Australia and the Asia-Pacific region since 1997 [10,19,20].
Subgenogroups C1 and C2 have been dominant in the USA
and Europe since 1980s, C3 was first described in Korea in
2000, and C4 and C5 have been observed in the Asia-Pacific
region since 1997 [10,11,14,21-23]. These epidemic patterns
show that one subgenogroup may circulate in the same region
for a long period (e.g., subgenogroup C4 in China) or cause
outbreaks in different countries (e.g., subgenogroup C1 in the
USA and Europe).
In 1998, a large HFMD outbreak caused by subgenogroups
C2, B4, and C4 was reported in Taiwan. Subsequently, the
subgenogroup B4 resulted in major outbreaks from 1999 to
2003, followed by subgenogroup C4 from 2004 to 2005, and
subgenogroup B5 in 2008 [14,24,25]. In addition, a small
number of subgenogroups, the C5, C4 and C2-like strains,
were also observed in 2008 [14]. A rapid change of
subgenogroups in Taiwan resulted in the possibility of severe
outbreaks. Because of disease control and vaccine
development needs, we analyzed genetic and antigenic
diversity of the EV-71 isolates collected by the surveillance
system from 2009 to 2012 and of reference strains by
phylogenetic analyses and neutralization tests.
Materials and Methods
Ethics Statement
The study was approved by the Institutional Review Board
(IRB) of Taiwan Centers for Disease Control (Taiwan CDC). All
virus strains isolated from patients in this study were de-
identified according to the IRB approved protocol of Taiwan
CDC to meet the patient confidentiality guidelines. Based on
the Taiwan’s Communicable Disease Control Act, an informed
consent is not necessary for collecting clinical specimens from
patients with suspected notifiable communicable diseases.
However, if these samples were used for research purposes,
they must be de-identified prior to publication. In the study, the
EV-71 virus strains have been de-linked from patient identifiers.
Specimen collection, virus isolation and identification
The EV-71 viruses used in this study were collected and
isolated by the surveillance systems under the Taiwan CDC, as
previously described [14]. Throat swabs, rectal swabs, or stool
samples taken from patients with HFMD, herpangina, and other
symptoms related to EV infection were used for virus isolation.
The isolates were then identified by immunofluorescence assay
(IFA) using commercial antibodies against enteroviruses (pan-
enterovirus) and specifically against EV-71 (Light Diagnostics,
Millipore Corporation, Billerica, MA, USA) according to the
protocol recommended by the manufacturer. The cell culture
infective dose (CCID50) of the virus was calculated by the Reed
and Muench method [26].
Sequencing and phylogenetic analysis
Viral RNA was extracted using a QIAamp Viral RNA Mini Kit
(Qiagen, Santa Clara, CA) according to the manufacturer’s
instructions. One-step RT-PCR of the VP1 gene was
performed with primer set 159/162 [27], and full-length RT-PCR
was performed as previously described [28]. The products
were then sequenced using a BigDye Terminator v3.1 Cycle
Sequencing Kit and an automated sequencer ABI 3730
(Applied Biosystems, Foster City, CA, USA).
The Basic Local Alignment Search Tool (BLAST) and
Molecular Evolutionary Genetics Analysis (MEGA) program
were used for genotyping by sequence comparisons with
reference sequences in GenBank [29,30]. Phylogenetic trees
were constructed by the MEGA program, using the neighbor-
joining method with a bootstrap value of 1,000. The trees were
drawn to scale proportional to evolutionary distances. The
genetic distances were computed using the Tamura-Nei
method and were in the units of the number of base
substitutions per site. The rate variation among sites was
described by a gamma distribution. The differences in the
composition bias among sequences were considered in
evolutionary comparisons. All positions containing alignment
gaps and missing data were eliminated from the dataset. The
prototype coxsackievirus A16 G-10 strain was used as an out-
group. Recombination analysis of full-length genome
sequences was performed by using SimPlot software, as
previously described [19,31,32]. A substitution map was
generated based on the entropy values of amino acid
sequences with a selection criterion of 5%. Different types of
amino acids were indicated by different colors with single-letter
abbreviations.
Determination of neutralization antibody titers
To determine neutralization antibody titers, serum samples
and isolates from 35 EV-71-infected patients representing
different subgenogroups were used, including B4 (8 isolates),
B5b (7 isolates), B5c (3 isolates), C4a-1 (11 isolates in
2004-2005), C4a-2 (4 isolates in 2010-2011), C5 (1 isolate),
and C2-like subgenogroup (1 isolate). First, the sera were
inactivated at 56°C for 30 min; then, they were serially diluted
two-fold with DMEM. Next, the diluted antisera were mixed with
one hundred CCID50 viruses (50 μl) of different subgenogroups
(B4, B5b, B5c, C4a-1, C4a-2, C5, and C2-like) and placed in a
CO2 incubator at 36°C for 60 min. One hundred μl of RD cell
suspension containing approximately 3 x 104 cells was
subsequently added to each well, and the cytopathic effects
were recorded daily for the next 4 days. The neutralization
titers were defined as the highest dilution fold at which the
cytopathic effects were inhibited in 50% of cells. All
determinations were performed in duplicate.
Statistical analysis
The neutralization antibody titers were log2 transformed and
compared between the C2-like group and other subgenogroup
groups. Statistical analyses were performed using GraphPad
Antigenic and Genetic Diversity of Enterovirus 71
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Prism 5 software (GraphPad Software, San Diego, CA). The p
value < 0.05 is taken to indicate statistically significance.
Nucleotide sequence accession numbers
The 33 nucleotide sequences identified in this study were
deposited in the GenBank database under the following IDs:
KF134454-KF134486.
Results
Epidemiological and BLAST results of EV-71 isolates
The number and location of sampling sites for collecting
specimens, and the laboratory tests for diagnosis of
enteroviruses were not changed during the investigation. From
2009 to 2012, a total of 22,575 specimens were collected and
cultured for virus isolation, in which 10,775 enterovirus isolates
were confirmed by IFA. The isolation rates of enterovirus each
year during this period were 42.4% (2,440/5,749), 42.2%
(3,181/7,533), 57.7% (3,060/5,302), and 52.5% (2,094/3,991),
respectively. Among them, there were 961 EV-71 isolates in
Taiwan used for further study, including samples from 373
females and 588 males. No significant differences were
observed in gender distribution (p>0.05). The patients ranged
in age from 1 week to 97 years, and most (758/961, 78.9%) of
them were under 5, including 286 females and 472 males.
Four subgenogroups of EV-71, including 745 subgenogroup
B5 isolates, 14 C2 isolates, 199 C4 isolates, and 3 C5 isolates,
were identified based on the BLAST results of partial
nucleotide sequences of the VP1 gene (Figure 1). All isolates
showed extremely high identities with their respective reference
strains (>95%). Subgenogroup B5 was the dominant type in
2009, 2011, and 2012, while C4 was the dominant type in
2010. In addition, no subgenogroup C5 isolates had been
identified since 2011.
Phylogenetic analysis
The selection criteria of EV-71 isolates for phylogenetic
analysis were 1) to represent the predominant circulating
subgenogroup each year; 2) to exhibit unique characteristics;
and 3) to contain all subgenogroups from 2009 to 2012. Based
on BLAST genotyping results, 33 Taiwanese EV-71 isolates
collected from 2009 to 2012 in this study (17 subgenogroup B5
isolates, 5 subgenogroup C2 isolates, 10 subgenogroup C4
isolates, and 1 subgenogroup C5 isolate) and reference strains
recorded in the GenBank were chosen for further phylogenetic
analysis on a partial VP1 gene nucleotide sequence (403 bp,
nucleotide position 16–418) (Figure 2). The subgenogroup C4
isolates obtained in this study were genetically similar to each
other ranging from 96.5 to100% and shared a similarity of
96.5-97.7% with the Taiwanese C4 strains isolated in 2008,
which were thought to be imported from China. The C5
subgenogroup isolate was clustered with previous Taiwanese
isolates and reference strains. In addition, the subgenogroup
C2 isolates were clustered with different reference strains; the
isolates in 2009 were clustered with older Taiwanese strains
from 1998, but the isolates from 2012 were clustered with
strains isolated in Japan and Europe from 2007 to 2010.
Interestingly, almost all subgenogroup B5 isolates were divided
into three clusters, B5a, B5b and B5c. The genetic distances
from averaging over all sequence pairs within each cluster
were determined as 0.009, 0.010 and 0.014 for B5a, B5b and
Figure 1.  Subgenogrouping of enterovirus 71 (EV-71) isolates from Taiwan from 2009 to 2012 according to the BLAST
results.  The subgenogroup was determined by BLAST analysis of partial nucleotide sequences of the VP1 gene. There were 745
subgenogroup B5 isolates, 14 subgenogroup C2 isolates, 3 subgenogroup C5 isolate, and 199 subgenogroup C4 isolates identified
according to the BLAST analysis.
doi: 10.1371/journal.pone.0080942.g001
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B5c, respectively. The B5a cluster was composed of isolates
from Japan and Malaysia. The Taiwanese isolates from 2009
(except one isolate 2009-10657) and some from 2010 were
clustered with the strains isolated from 2007 to 2008 (B5b).
The other isolates from 2010, the isolates from 2011 to 2012,
and one Chinese strain from 2009 were clustered alone (B5c).
The isolate 2009-10657 could not be grouped within these
three clusters.
Sequence variation and recombination analysis
To compare the genetic variations among the B5a, B5b and
B5c isolates, the full-length genome sequence of one
subgenogroup B5c isolate (A2011125), and the VP1 gene
sequences of 15 subgenogroup B5 isolates were determined.
In the recombination analysis of full-length genome sequences,
no recombination event was observed for the B5c isolate (data
not shown), and there was a high similarity (96.6%) of the full-
length genome nucleotide sequences between the B5b
(2007-08747) and B5c (A2011125) isolates.
Based on the phylogenetic analysis of VP1 gene sequences
(Figure 3), four different conserved amino acids were identified
between the genogroups B and C of EV-71. For instance, E
(glutamic acid) was at position 43, T (threonine) was at position
58, 184, and S (serine) was at position 240 for genogroup B,
but these were replaced by K (lysine), A (alanine), S, and T,
respectively, for genogroup C. However, no specific amino acid
substitution correlated to different subgenogroups was
observed among B5a, B5b and B5c isolates.
Interestingly, there were four subgenogroup B5 isolates
displaying an amino acid substitution at position 145, and three
of them were isolated from the patients with acute flaccid
paralysis (AFP). A2011125 and A2011140 exhibited an E145Q
substitution, while A2011116 exhibited an E145R (Figure 3).
Neutralization antibody titers and cross-reactivity
between EV-71 subgenogroups
Serum samples were collected from the patients who were
infected with EV-71 subgenogroups B4, C4 (C4a-1 and C4a-2),
B5 (B5b and B5c), C2-like and C5 in 2002-2003, 2004-2005,
2010-2011, 2008, 2011, 2008, and 2006, respectively (Table
S1). The serum sample against C2-like virus was obtained
from the C2-like-infected patient’s brother. Both patients
showed enterovirus infection-related symptoms and sought
medical advice. Most of the serum samples were collected
during the recovery-phase (12-34 days post infection), except
for two samples collected in the acute-phase (3-7 days post
infection). Neutralization antibody titers against their homo-
subgenogroup viruses were 1:32 to 1:8,192 (Table 1). Cross-
reactive neutralizing antibody titers against EV-71 strains with
different subgenogroups are shown in Figure 4. A diversity of
neutralizing antibody titers was observed, with a range of
32,768 to <8. No clear pattern of antigenic variations was
observed among these strains with different subgenogroups,
except C2-like. Over all, the patients infected with
subgenogroup B4, C4 (C4a-1 and C4a-2), B5 (B5b and B5c),
and C5 had lower neutralizing antibody titers against the
subgenogroup C2-like strain than against other strains
Figure 2.  Phylogenetic analysis of enterovirus 71 (EV-71)
based on partial nucleotide sequences of the VP1 gene
(nucleotide position 16-418).  Phylogenetic analysis was
performed based on the partial nucleotide sequences of the
VP1 gene of reference strains and Taiwanese isolates. The
phylogenetic tree was constructed with MEGA software by the
neighbor-joining method with 1,000 bootstrap replications. Only
bootstrap values greater than 70% were shown.
doi: 10.1371/journal.pone.0080942.g002
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(p<0.05). In addition, the C2-like infected patient had broad
cross-reactivity against all strains with different subgenogroups.
Discussion
EV-71 infection, one of the common enterovirus infections in
the Western Pacific region, was associated with HFMD,
herpangina, and neurological diseases. Based on the
surveillance system in Taiwan, there were several EV-71
outbreaks caused by different subgenogroups in recent years,
for instance, subgenogroup B4 from 1999 to 2003,
subgenogroup C4 from 2004 to 2005, and subgenogroup B5 in
2008 [14,24]. In addition, there were minor outbreaks of
subgenogroup C4 from 2010 to 2011 and subgenogroup B5
from 2011 to 2012. The rapid changes of dominant
subgenogroups and potential for outbreaks made it important
to monitor the genetic and antigenic variations.
In this research, we reported the genetic and antigenic
diversity of EV-71 subgenogroups in Taiwan from 2009 to
2012, including the disappearance of subgenogroup C5, an
epidemic of subgenogroup C4, sporadic cases of
subgenogroup C2, and genetic changes of subgenogroup B5.
This type of circulation was not similar to that in other
countries; for example, genogroup C was the main genogroup
in the United Kingdom and mainland China for years [23,33].
Subgenogroup C5 was first described in southern Vietnam in
2005, and resulted in an outbreak with neurological
manifestations [11]. In 2006, subgenogroup C5 was first
isolated in Taiwan [19], and it was found in a small number of
cases until 2010, based on our surveillance results. Although
subgenogroup C5 was not observed in Taiwan in 2011 and
2012, the possibility of C5 re-emerging could not be ignored
because B5 caused outbreaks in 2008 and re-emerged in
2011-2012.
Subgenogroup C2, the main genogroup of most EV-71
isolates from the 1998 epidemic in Taiwan, was detected in a
small number of cases after 10 years. Interestingly, the C2
isolates in 2009 were clustered with those in 1998, but the
Figure 3.  Phylogenetic analysis of enterovirus 71 (EV-71) based on complete nucleotide sequences of the VP1
gene.  Phylogenetic analysis was performed based on the complete nucleotide sequences of the VP1 gene of reference strains and
Taiwanese isolates. The phylogenetic tree was constructed with MEGA software by the neighbor-joining method with 1,000
bootstrap replications. Only bootstrap values of over 70% were shown. Amino acid substitutions were visualized through a
proteotyping map with colored indications in single-letter abbreviations. Each column represented the amino acid position indicated
with a selection criterion of 5%.
doi: 10.1371/journal.pone.0080942.g003
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isolates in 2012 were clustered with recent isolates, for
example, isolates from Japan in 2010 and those from the
United Kingdom in 2010. This clustering suggests that these
C2 isolates evolved and spread worldwide. Additionally, the C2
isolates from Taiwan in 2012 were collected from different
patients at different locations in different months,
demonstrating that this subgenogroup was not a cluster event
Table 1. Neutralization antibody titers of 35 serum samples





Number of serum sample with indicated neutralization
antibody titer Total
 1:32 1:256 1:512 1:1,024 1:2,048 1:4,096 1:8,192  
B4 0 1a 0 2 3 1 1 8
C4a-2 0 0 0 1 0 2 1 4
C4a-1 1 1 0 1 5 1 2 11
B5b 0 0 1 0 3 1 2 7
B5c 0 0 0 0 1 1 1 3
C5 0 0 1 0 0 0 0 1
C2-like 0 0 1b 0 0 0 0 1
a. Serum sample was collected in acute-phase (3 days post infection).
b. Serum sample was collected in acute-phase (7 days post infection).
doi: 10.1371/journal.pone.0080942.t001
but had circulated for a period of time in a small number of
cases. Moreover, a closely related phylogeny between these
recent C2 isolates was suspected because of the high similarity
(>98%) of the partial VP1 region.
C4, the main subgenogroup in China, has circulated and
spread in recent years. There were two clusters of C4 (C4a
and C4b) from 1998 to 2010, with a shift from cluster C4b to
C4a in 2003–2004 [21,33]. The C4b cluster was first isolated in
Taiwan in 1998, and the C4a cluster caused outbreaks in
2004-2005 [24]. In 2008, several C4 isolates (C4a) identified in
Taiwan were thought to have been transmitted from China
because these isolates correlated genetically with C4 strains
from China but not with those isolated in Taiwan in 2004-2005
[14]. Furthermore, this C4 subgenogroup caused small
outbreaks in 2010-2011 based on the present surveillance
results. Additional studies are needed to clarify why
subgenogroup C4 caused different epidemic patterns. For
example, several large outbreaks occurred in China in specific
years, but only small ones occurred in Taiwan. However, we
could not exclude the effects due to the diversity of EV-71
circulation and herd immunity in Taiwan.
The subgenogroup B5 has circulated in Taiwan since 2007
and caused outbreaks in 2008, although there were two
isolates sporadically detected in 2003. Towards the end of
2009, a genogroup shift (B5 to C4) and drift (B5b to B5c) of
circulating EV-71 was observed. Isolate 2009-10657 was
thought to be the intermediate between B5b and B5c. Although
the epidemics in 2011-2012 may be partially attributed to the
Figure 4.  Serum neutralization antibody titers against different subgenogroups of enterovirus 71 (EV-71).  The 35 serum
samples were tested at two-fold serial dilutions against one hundred CCID50 of EV-71 viruses. The neutralization titers were defined
as the highest dilution fold at which the cytopathic effects were inhibited in 50% of cells. The titer values were log2 transformed and
were represented by different colors, as indicated by the log2 scale. The star symbol indicates a significant difference when
compared to subgenogroup C2-like group (p<0.05).
doi: 10.1371/journal.pone.0080942.g004
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emerging subgenogroup B5c of EV-71, no evident divergence
of antigenic relationship between subgenogroup B5b and B5c
was displayed in this study. In addition to the viral factor, herd
immunity and the susceptible population (infants, children, and
adolescents) may be important factors in EV-71 epidemics
because these groups may not have experienced the previous
outbreak in 2008 [14] or produced the necessary antibodies
yet. However, the genogrouping of EV-71 does not absolutely
reflect the antigenicity of the strains examined [34].
An amino acid mutation at position 145 of VP1 was
associated with increased virulence in mice [8]. In addition, the
E145Q substitution was observed in more virulent strains [35],
and this residue of genogroup B was under positive selection
based on the results of evolutionary analysis with single-
likelihood ancestor counting and fixed-effects likelihood
methods [36]. In this study, we described three subgenogroup
B5 isolates with substitutions at position 145 that were isolated
from patients with AFP. These results emphasize the
importance of substitution at position 145, and additional
studies of receptor binding and virulence correlation with this
substitution are needed. However, another genetic determinant
(K244E) of mouse adaptation and virulence was not observed
in this study [7].
Few studies of cross-protection among different genogroups
of EV-71 were available [14,37,38]. Furthermore, the
antigenicities of EV-71 strains varied based on different
reports. Different genogroups displayed less than 4-fold
differences in neutralizing antibody titers based on a
serological survey in Japan [38]. However, antigenic
differences were detected between genogroup B and C, and
also between B5 and B4 viruses [36]. By using rabbit
antiserum, anti-B2 could cross-neutralize B0, B1 and B2
viruses but not C1 or C2 viruses. On the other hand, anti-C1
rabbit serum could neutralize both genogroup B and C viruses
[39]. Mao et al. detected different cross-neutralization
capacities against different strains with the same
subgenogroup (C4a) in animal sera [40]. The variations
observed between different reports might be due to the
different sample sizes, virus strains, sera, experimental
methods, and cell lines used in the neutralization tests.
However, standard protocols, including standard sera and
viruses, may be used to minimize variations.
In this study, there were 35 strains and corresponding serum
samples used to analyze the cross-protection and antigenic
diversity among different subgenogroups (C4a, C5, B4, B5b,
B5c, and C2-like) of EV-71. The subgenogroup C2-like strain
exhibited evident antigenic diversity. All sera were positive
against the 35 EV-71 strains, but the titers of neutralization
antibody produced varied. Most of the patients infected with
subgenogroup B4, C4, B5, and C5 had lower neutralizing
antibody titers against the subgenogroup C2-like strain than
against other strains, whereas the C2-like infected patient had
broad cross-reactivity against all strains with different
subgenogroups. These results were not unexpected because
C2-like was a recombinant strain originating from
subgenogroup C2 and B3 [14]. Since the C2-like serum was
collected in the acute-phase while most other serum samples
were collected in the recovery-phase, we cannot rule out the
possibility that the serum collected at different stages may
influence the neutralization antibody titers. However, the rabbit
antisera against C2-like strain, prepared by our laboratory,
were used for conducting neutralization tests for EV-71 viruses
in the study, and showed similar results as using patients’ sera
(Figure S1). Although C2-like viruses did not spread widely, the
antigenic diversity of these viruses may lead to concern for the
development of EV-71 vaccines. The key factors for selecting
candidate vaccine strains include high virus titers, the ability to
induce strong neutralization antibody titers, and broad cross-
neutralization effects. These serum samples and the
serological data obtained from the present study may be
helpful to select a suitable vaccine strain and to recognize
antigenic variants of EV-71.
In conclusion, first, the genetic changes of circulating EV-71
in Taiwan in recent years were described, including the re-
emergence of subgenogroup B5, the short circulation of C4,
the disappearance of C5, and the sporadic occurrence of
subgenogroup C2. Second, the antigenicities of different
subgenogroups of EV-71 were evaluated by using serum
samples obtained from patients with EV-71 infections. These
results may be useful for the surveillance and prevention of
EV-71, and the development of vaccines.
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